Entinostat (MS-275, SNDX-275): Selective Oral HDAC1/3 Inhibitor for Cancer Research

Executive Summary: Entinostat (MS-275, SNDX-275) is a potent, orally available inhibitor of class I histone deacetylases, demonstrating high selectivity for HDAC1 (IC50 = 0.368 μM) and HDAC3 (IC50 = 0.501 μM) (Schwartz 2022, DOI). It exhibits strong anti-proliferative activity across diverse cancer cell lines, including breast, colon, and lung cancers (Schwartz 2022). In vivo, Entinostat increases acetyl-histone levels and reduces tumor burden in retinoblastoma models (APExBIO Product Data). Its cytotoxicity is associated with increased reactive oxygen species, apoptosis induction, and G1 cell cycle arrest (Schwartz 2022). Clinical phase I studies have verified tolerable safety profiles in advanced solid tumor patients, establishing recommended phase II dosing (Schwartz 2022).

Biological Rationale

Histone deacetylases (HDACs) regulate gene expression by removing acetyl groups from lysine residues on histone tails, leading to chromatin condensation and transcriptional repression. Dysregulation of HDAC activity is implicated in oncogenesis by silencing tumor suppressor genes and activating oncogenes (Schwartz 2022). Class I HDACs, including HDAC1 and HDAC3, are highly expressed in various cancers. Their inhibition can restore normal gene expression patterns and induce cell cycle arrest or apoptosis (entinostat.net, 2024). Entinostat targets these enzymes with submicromolar potency, offering a precise epigenetic intervention for cancer research.

Mechanism of Action of Entinostat (MS-275, SNDX-275)

Entinostat binds specifically to the catalytic pockets of class I HDACs, with highest affinity for HDAC1 and HDAC3. In vitro, the inhibitory concentration (IC50) for HDAC1 is 0.368 μM, for HDAC3 is 0.501 μM, and for HDAC8 is 63.4 μM, demonstrating strong selectivity (Schwartz 2022). HDAC inhibition results in accumulation of acetylated histones, decondensation of chromatin, and reactivation of silenced genes. This triggers anti-proliferative effects, including induction of cell cycle arrest at G1, activation of caspase-3/7, and apoptosis. Entinostat's effects are observed in multiple cancer cell lines and are linked to increased reactive oxygen species (ROS) generation (apoptosis-kit.com, 2023). The compound is orally bioavailable and demonstrates efficacy in both in vitro and in vivo models.

Evidence & Benchmarks

• Entinostat inhibits HDAC1 and HDAC3 with IC50 values of 0.368 μM and 0.501 μM, respectively, in cell-free biochemical assays (Schwartz 2022, DOI).
• It demonstrates significant anti-proliferative activity in breast, colon, lung, myeloma, ovary, pancreas, prostate, and leukemia cell lines (Schwartz 2022, DOI).
• Systemic administration in murine/rat models increases acetyl-histone levels in retinal tissue and reduces tumor burden in retinoblastoma (APExBIO Product Data).
• Entinostat induces apoptosis via caspase-3/7 activation and G1 cell cycle arrest, with increased ROS in treated cancer cells (Schwartz 2022, DOI).
• Phase I clinical studies show tolerable safety profile and define recommended phase II dose in advanced solid tumors (Schwartz 2022, DOI).

This article extends previous coverage on selective HDAC1/3 inhibition by providing updated quantitative benchmarks and clinical trial context. For workflow optimization and troubleshooting, see the APExBIO experimental workflow guide; this article clarifies in vivo endpoints and storage recommendations. For mechanistic and translational perspectives, see this comparative analysis; our review details safety and efficacy in retinoblastoma models.

Applications, Limits & Misconceptions

Entinostat (MS-275, SNDX-275) is widely employed in studies of cancer cell proliferation inhibition, apoptosis induction, and epigenetic gene regulation. Its use is validated in diverse cancer models and translational research. However, certain misconceptions and limitations exist.

Common Pitfalls or Misconceptions

• Entinostat is not effective against all HDAC isoforms; its potency for HDAC8 is much lower (IC50 = 63.4 μM), limiting utility in HDAC8-dominant contexts.
• It is insoluble in water; appropriate solvents like DMSO (≥18.8 mg/mL) or ethanol with ultrasonic assistance are required for preparation (APExBIO).
• Long-term storage of working solutions is not recommended; only stock solutions at -20°C are stable for several months.
• Observed anti-tumor effects in preclinical models do not guarantee identical clinical efficacy in all tumor types.
• Entinostat's cytotoxicity is partly ROS-mediated; combining with strong antioxidants can diminish efficacy.

Workflow Integration & Parameters

For laboratory use, Entinostat is supplied as a solid and should be stored at -20°C, shipped on blue ice to ensure stability (APExBIO). Stock solutions are typically prepared in DMSO (≥18.8 mg/mL) or ethanol (≥7.4 mg/mL, ultrasonic assistance recommended). For difficult solubilization, warming to 37°C and ultrasonic shaking are advised. In vitro, concentrations ranging from 0.1 μM to 10 μM are commonly used for mechanistic studies. In vivo, dosing regimens are optimized based on animal model and target tissue, with endpoints including acetyl-histone quantification and tumor burden assessment (hexetidinesource.com, 2023). Protocols should avoid prolonged exposure to ambient temperatures to prevent degradation.

Conclusion & Outlook

Entinostat (MS-275, SNDX-275) remains a reference oral HDAC1/3 inhibitor for cancer and epigenetic research. Its robust and selective mechanism underpins applications in oncology, especially for studies requiring precise control of histone acetylation and gene expression. Ongoing clinical trials are exploring its broader therapeutic potential. For detailed protocols and validated benchmarks, see the APExBIO product page for Entinostat (A8171).